Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMF1P6W)

Drug Name
SU 6656 Drug Info
Synonyms
su6656; 330161-87-0; SU-6656; SU6656; CHEMBL605003; (3z)-N,N-Dimethyl-2-Oxo-3-(4,5,6,7-Tetrahydro-1h-Indol-2-Ylmethylidene)-2,3-Dihydro-1h-Indole-5-Sulfonamide; (3Z)-N,N-dimethyl-2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylidene)-1H-indole-5-sulfonamide; SR-01000076237; 2,3-Dihydro-N,N-dimethyl-2-oxo-3-[(4,5,6,7-tetrahydro-1H-indol-2-yl)methylene]-1H-indole-5-sulfonamide; AC1NSM2X; Lopac-S-9692; Lopac0_000979; MLS002153475; GTPL6044; EX-A584; MolPort-003-959-609; HMS3229I04; HMS2232C04
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5312137
ChEBI ID
CHEMBL605003
TTD Drug ID
DMF1P6W

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting LCK tyrosine protein kinase (LCK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [4]
VX-680 DM93YKJ Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
JNJ-26483327 DMSQ3AZ Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
ISIS-CRP DMQDUG4 Cardiovascular disease BA00-BE2Z Phase 1 [2]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [6]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [6]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [7]
CI-1040 DMF3DZX Discovery agent N.A. Investigative [6]
AMP-PNP DMTOK1D Discovery agent N.A. Investigative [8]
BMS-536924 DMXJB4N Discovery agent N.A. Investigative [9]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting AMP-activated protein kinase (AMPK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acadesine DM1RMF5 Diabetic complication 5A2Y Phase 3 [10]
MB-11055 DM3RBJW Fatty liver disease DB92.Z Phase 2 [11]
Imeglimin DMMQFG2 Diabetic complication 5A2Y Phase 2 [12]
PXL-770 DMNSRY7 Non-alcoholic fatty liver disease DB92 Phase 2 [13]
ENERGI-F701 DMMIHSO Alopecia ED70 Phase 2 [14]
O-304 DMXM34I Type 2 diabetes 5A11 Phase 2 [15]
IM156 DM4MY9C Solid tumour/cancer 2A00-2F9Z Phase 1 [16]
Phenformin DMQ52JG Diabetic complication 5A2Y Withdrawn from market [17]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [7]
PMID23639540C13a DMLXOAQ Discovery agent N.A. Investigative [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Aurora B messenger RNA (AURKB mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PHA-739358 DMGYBZI Prostate cancer 2C82.0 Phase 2 [19]
Indirubin-3'-monoxime DMLRQH0 Discovery agent N.A. Investigative [20]
6-bromoindirubin-3-oxime DM12WYV Discovery agent N.A. Investigative [20]
7-fluoroindirubin-3-oxime DMQD34N Discovery agent N.A. Investigative [20]
PMID21742770C1 DME3JMH Discovery agent N.A. Investigative [21]
Indirubin-3-acetoxime DM3UR1E Discovery agent N.A. Investigative [20]
CGP-57380 DMFPOUC Discovery agent N.A. Investigative [2]
PMID20855207C25 DMNEB6J Discovery agent N.A. Investigative [22]
Indirubin-3-methoxime DMZ5ODC Discovery agent N.A. Investigative [20]
4-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine DM9MPHF Discovery agent N.A. Investigative [23]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Proto-oncogene c-Src (SRC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [4]
Bosutinib DMTI8YE Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [4]
SKI-758 DMQ8E9R Ischemia 8B10-8B11 Approved [24]
Herbimycin A DM6YWBF Solid tumour/cancer 2A00-2F9Z Approved [25]
AL3818 DM3WP0N Alveolar soft part sarcoma 2A60-2C35 Phase 3 [16]
CP-868596 DMZIM37 Gastrointestinal cancer 2C11 Phase 3 [16]
Masitinib DMRSNEU Amyotrophic lateral sclerosis 8B60.0 Phase 3 [26]
KX-01 DMF0NA9 Actinic keratosis EK90.0 Phase 3 [27]
Saracatinib DMBLHGP Hematologic tumour 2B33.Y Phase 2 [28]
TPX-0046 DMIVE67 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [29]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Aurora kinase C (AURKC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PHA-739358 DMGYBZI Prostate cancer 2C82.0 Phase 2 [19]
ABT-348 DMMZOYN Haematological malignancy 2B33.Y Phase 2 [30]
HPP-607 DM5VSZR Solid tumour/cancer 2A00-2F9Z Phase 1 [31]
AMG 900 DMASGXJ Solid tumour/cancer 2A00-2F9Z Phase 1 [32]
SNS-314 DMAC5F2 Solid tumour/cancer 2A00-2F9Z Phase 1 [33]
GSK1070916 DMXRPT6 Advanced solid tumour 2A00-2F9Z Phase 1 [34]
GSK1070916A DMCJUI9 Solid tumour/cancer 2A00-2F9Z Phase 1 [34]
MK-6592 DMB5NOI Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 1 [35]
Indirubin-3'-monoxime DMLRQH0 Discovery agent N.A. Investigative [20]
6-bromoindirubin-3-oxime DM12WYV Discovery agent N.A. Investigative [20]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Keratin, type I cytoskeletal 18 (KRT18)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [36]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [37]
Selenium DM25CGV N. A. N. A. Approved [38]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [39]
Methotrexate DM2TEOL Anterior urethra cancer Approved [40]
Quercetin DM3NC4M Obesity 5B81 Approved [41]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [42]
Panobinostat DM58WKG Chronic graft versus host disease Approved [43]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [44]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [45]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Keratin, type II cytoskeletal 8 (KRT8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [36]
Selenium DM25CGV N. A. N. A. Approved [38]
Methotrexate DM2TEOL Anterior urethra cancer Approved [40]
Quercetin DM3NC4M Obesity 5B81 Approved [46]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [47]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [36]
Panobinostat DM58WKG Chronic graft versus host disease Approved [43]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [48]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [49]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [50]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Catenin beta-1 (CTNNB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [51]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [52]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [53]
Quercetin DM3NC4M Obesity 5B81 Approved [54]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [55]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [56]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [57]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [58]
Testosterone DM7HUNW Hot flushes GA30 Approved [59]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [60]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By POU domain, class 5, transcription factor 1 (POU5F1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [61]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [62]
Quercetin DM3NC4M Obesity 5B81 Approved [63]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [64]
Panobinostat DM58WKG Chronic graft versus host disease Approved [43]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [65]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [66]
Testosterone DM7HUNW Hot flushes GA30 Approved [67]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [68]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [69]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
AMP-activated protein kinase (AMPK) TTLAFZV AAPK1_HUMAN; AAKB1_HUMAN; AAKG1_HUMAN Inhibitor [2]
Aurora B messenger RNA (AURKB mRNA) TT9RTBL AURKB_HUMAN Inhibitor [2]
Aurora kinase C (AURKC) TTLYXIT AURKC_HUMAN Inhibitor [2]
LCK tyrosine protein kinase (LCK) TT860QF LCK_HUMAN Inhibitor [2]
Proto-oncogene c-Src (SRC) TT6PKBN SRC_HUMAN Inhibitor [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Protein Interaction/Cellular Processes [3]
Keratin, type I cytoskeletal 18 (KRT18) OTVLQFIP K1C18_HUMAN Gene/Protein Processing [3]
Keratin, type II cytoskeletal 8 (KRT8) OTTM4X11 K2C8_HUMAN Gene/Protein Processing [3]
POU domain, class 5, transcription factor 1 (POU5F1) OTDHHN7O PO5F1_HUMAN Gene/Protein Processing [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6044).
2 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
3 A small molecule inhibitor of SRC family kinases promotes simple epithelial differentiation of human pluripotent stem cells. PLoS One. 2013;8(3):e60016. doi: 10.1371/journal.pone.0060016. Epub 2013 Mar 20.
4 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
5 National Cancer Institute Drug Dictionary (drug id 596693).
6 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
7 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
8 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
9 Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
10 Acadesine, an adenosine-regulating agent with the potential for widespread indications. Expert Opin Pharmacother. 2008 Aug;9(12):2137-44.
11 Antidiabetes and antiobesity effect of cryptotanshinone via activation of AMP-activated protein kinase.Mol Pharmacol.2007 Jul;72(1):62-72.
12 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032542)
13 Clinical pipeline report, company report or official report of Poxel SA.
14 Clinical pipeline report, company report or official report of Energenesis Biomedical.
15 Clinical pipeline report, company report or official report of Betagenon.
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 Complementary regulation of TBC1D1 and AS160 by growth factors, insulin and AMPK activators. Biochem J. 2008 Jan 15;409(2):449-59.
18 Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3248-52.
19 Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J Med Chem. 2005 Apr 21;48(8):3080-4.
20 An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted in... J Med Chem. 2007 Aug 23;50(17):4027-37.
21 A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.
22 Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Bioorg Med Chem Lett. 2010 Nov 15;20(22):6739-43.
23 Discovery of a new series of Aurora inhibitors through truncation of GSK1070916. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2552-5.
24 Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.
25 In vivo antitumor activity of herbimycin A, a tyrosine kinase inhibitor, targeted against BCR/ABL oncoprotein in mice bearing BCR/ABL-transfected cells. Leuk Res. 1994 Nov;18(11):867-73.
26 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
27 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
28 Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Expert Opin Investig Drugs.2010 Aug;19(8):931-45.
29 Clinical pipeline report, company report or official report of Turning Point Therapeutics.
30 Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families. J Pharmacol Exp Ther. 2012 Dec;343(3):617-27.
31 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1936).
32 Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines. Cancer Res. 2010 Dec 1;70(23):9846-54.
33 SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo. Cancer Chemother Pharmacol. 2010 Mar;65(4):707-17.
34 Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase. J Med Chem. 2010 May 27;53(10):3973-4001.
35 Clinical experience with aurora kinase inhibitors: a review. Oncologist. 2009 Aug;14(8):780-93.
36 Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
37 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
38 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
39 The stability of cytokeratin 18 in human liver cells during colchicine-induced microtubule disruption. Food Chem Toxicol. 2001 Jan;39(1):85-9. doi: 10.1016/s0278-6915(00)00113-7.
40 Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
41 Identification of biomarkers for the initiation of apoptosis in human preneoplastic colonocytes by proteome analysis. Int J Cancer. 2004 Mar 20;109(2):220-9. doi: 10.1002/ijc.11692.
42 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
43 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
44 Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. Prostate. 2009 May 15;69(7):744-54. doi: 10.1002/pros.20923.
45 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
46 The effects of quercetin on SW480 human colon carcinoma cells: a proteomic study. Nutr J. 2005 Mar 4;4:11.
47 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
48 Proteomics-based identification of differentially abundant proteins from human keratinocytes exposed to arsenic trioxide. J Proteomics Bioinform. 2014 Jul;7(7):166-178.
49 Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol Sci. 2011 Mar;120(1):109-22.
50 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
51 Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. Sci Rep. 2020 Feb 14;10(1):2687. doi: 10.1038/s41598-020-59468-4.
52 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
53 Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol. 2008 Mar 31;583(1):26-31. doi: 10.1016/j.ejphar.2007.12.034. Epub 2008 Feb 5.
54 Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
55 Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation. Mol Cell Endocrinol. 2012 Jan 2;348(1):260-9. doi: 10.1016/j.mce.2011.09.002. Epub 2011 Sep 6.
56 Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Leuk Res. 2008 Nov;32(11):1674-83. doi: 10.1016/j.leukres.2008.03.039. Epub 2008 May 15.
57 Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene. 2006 Oct 19;25(49):6447-56. doi: 10.1038/sj.onc.1209658. Epub 2006 Jul 31.
58 Benzene metabolite hydroquinone induces apoptosis of bone marrow mononuclear cells through inhibition of -catenin signaling. Toxicol In Vitro. 2018 Feb;46:361-369. doi: 10.1016/j.tiv.2017.08.018. Epub 2017 Sep 5.
59 Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways. Toxicol In Vitro. 2017 Apr;40:324-335. doi: 10.1016/j.tiv.2017.01.019. Epub 2017 Feb 2.
60 Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.
61 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
62 Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
63 Quercetin in elimination of tumor initiating stem-like and mesenchymal transformation property in head and neck cancer. Head Neck. 2013 Mar;35(3):413-9. doi: 10.1002/hed.22982. Epub 2012 Mar 16.
64 Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim Biophys Acta. 2005 Oct 15;1731(1):48-56. doi: 10.1016/j.bbaexp.2005.08.006. Epub 2005 Sep 1.
65 The antipsychotic chlorpromazine suppresses YAP signaling, stemness properties, and drug resistance in breast cancer cells. Chem Biol Interact. 2019 Apr 1;302:28-35. doi: 10.1016/j.cbi.2019.01.033. Epub 2019 Jan 28.
66 Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. Clin Transl Med. 2021 Feb;11(2):e335. doi: 10.1002/ctm2.335.
67 Altered expression of genes identified in rats with prostatic chronic inflammation in a prostate spheroid model treated by estradiol/testosterone. J Toxicol Sci. 2021;46(11):515-523. doi: 10.2131/jts.46.515.
68 Antiepileptic drugs are endocrine disruptors for the human fetal testis ex vivo. Toxicol Sci. 2023 Sep 28;195(2):169-183. doi: 10.1093/toxsci/kfad076.
69 Effects of Exposure to Acetaminophen and Ibuprofen on Fetal Germ Cell Development in Both Sexes in Rodent and Human Using Multiple Experimental Systems. Environ Health Perspect. 2018 Apr 16;126(4):047006. doi: 10.1289/EHP2307.